Controversial Shift in Hepatitis B Vaccine Policy Sparks Debate

A U.S. advisory committee has voted to end the broad recommendation for hepatitis B vaccination in newborns, sparking significant debate. Critics argue the change could lead to increased infections and distrust in vaccination policies, while proponents emphasize the low risk of infection in young children.

In a surprising move, the Advisory Committee on Immunization Practices (ACIP) has voted to remove the sweeping recommendation for hepatitis B vaccination at birth. This decision, which marks a significant departure from previous healthcare policies, has ignited intense discussions among medical professionals and parents alike.

Critics of the decision, including Senator Bill Cassidy and vaccine expert Dorit Reiss, express concerns that the change could lead to a rise in hepatitis B infections among infants and children. They argue that the vaccine remains a safe and effective safeguard against the disease, which once infected thousands of newborns annually before the introduction of the birth dose recommendation.

On the other hand, some ACIP members like Retsef Levi, emphasize the low infection risk for newborns born to hepatitis B-negative mothers, questioning the necessity of immediate vaccination. The change reflects a growing debate over parental choice, public health strategy, and the balance between individual and collective health interests.

(With inputs from agencies.)